purine has been researched along with Severe Combined Immunodeficiency in 2 studies
1H-purine : The 1H-tautomer of purine.
3H-purine : The 3H-tautomer of purine.
9H-purine : The 9H-tautomer of purine.
7H-purine : The 7H-tautomer of purine.
Severe Combined Immunodeficiency: Group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. It is inherited as an X-linked or autosomal recessive defect. Mutations occurring in many different genes cause human Severe Combined Immunodeficiency (SCID).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cassani, B | 1 |
| Montini, E | 1 |
| Maruggi, G | 1 |
| Ambrosi, A | 1 |
| Mirolo, M | 1 |
| Selleri, S | 1 |
| Biral, E | 1 |
| Frugnoli, I | 1 |
| Hernandez-Trujillo, V | 1 |
| Di Serio, C | 1 |
| Roncarolo, MG | 1 |
| Naldini, L | 1 |
| Mavilio, F | 1 |
| Aiuti, A | 1 |
| Sakiyama, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of ADA-SCID by Gene Therapy on Somatic Cells[NCT00599781] | Phase 1/Phase 2 | 8 participants (Actual) | Interventional | 1992-03-31 | Completed | ||
| ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCID[NCT00598481] | Phase 2 | 12 participants (Actual) | Interventional | 2002-10-02 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Severe infections were defined as those that required hospitalization or those that prolonged hospitalization. The rate of infection was estimated as number of severe infections over person-years of observation (free from severe infections) before and after treatment administration. The first 3 months after gene therapy were not considered in the post-gene therapy analysis, because all subjects were hospitalized during this period. (NCT00598481)
Timeframe: Before Treatment and 3-months post-treatment up to 3 years
| Intervention | Severe Infections per person year (Number) |
|---|---|
| Severe Infections (Before Gene Therapy) | 1.1 |
| Severe Infections (After Gene Therapy) | 0.429 |
From post-treatment to up to 3 years (NCT00598481)
Timeframe: baseline to 3 years post gene therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Gene Therapy (Pivotal) | 12 |
T-lymphocyte counts (CD3+): mean T-lymphocyte at Baseline and 3 years post gene therapy. Samples were taken from peripheral venous whole blood and tested by cytofluorometry; values are means (10^6/L). (NCT00598481)
Timeframe: baseline up to 3 years post gene therapy
| Intervention | 10^6 cells/L (Geometric Mean) | |||
|---|---|---|---|---|
| Baseline | Year 1 | Year 2 | Year 3 | |
| Gene Therapy ITT Population | 112.5 | 348.3 | 633 | 831.1 |
1 review available for purine and Severe Combined Immunodeficiency
| Article | Year |
|---|---|
[Purine nucleoside phosphorylase deficiency].
Topics: Bone Marrow Transplantation; Diagnosis, Differential; Humans; Mutation; Prognosis; Purine-Nucleoside | 2000 |
1 trial available for purine and Severe Combined Immunodeficiency
| Article | Year |
|---|---|
Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy.
Topics: Adenosine Deaminase; Antigens, CD34; Biomarkers, Tumor; Cells, Cultured; Gene Expression Profiling; | 2009 |
Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy.
Topics: Adenosine Deaminase; Antigens, CD34; Biomarkers, Tumor; Cells, Cultured; Gene Expression Profiling; | 2009 |
Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy.
Topics: Adenosine Deaminase; Antigens, CD34; Biomarkers, Tumor; Cells, Cultured; Gene Expression Profiling; | 2009 |
Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy.
Topics: Adenosine Deaminase; Antigens, CD34; Biomarkers, Tumor; Cells, Cultured; Gene Expression Profiling; | 2009 |